查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1726298

全球間質幹細胞治療市場：市場規模、佔有率、趨勢分析（按類型、原料、適應症和地區）、細分市場預測（2025 年至 2030 年）

Mesenchymal Stem Cell Therapy Market Size, Share & Trends Analysis Report By Type (Autologous, Allogenic), By Source (Bone Marrow, Umbilical Cord, Adipose), By Disease Indication, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

間質幹細胞治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球間質幹細胞治療市場規模預計到2030年將達到2.966億美元，2025年至2030年期間的複合年成長率為23.5%。

間質幹細胞(MSC) 治療市場由於幾個關鍵因素而正在經歷顯著成長。其中一個主要促進因素是心血管疾病、糖尿病、自體免疫疾病和整形外科疾病等慢性疾病的盛行率不斷上升。 MSCs 具有獨特的再生和免疫調節特性，使其成為治療這些慢性疾病的有希望的候選藥物。它們能夠分化成各種細胞類型並促進組織修復，這增加了人們對基於 MSC 的療法的興趣。隨著全球慢性病負擔不斷增加，對 MSC 療法等創新治療方法的需求預計將相應成長。

推動 MSC 治療市場發展的另一個關鍵因素是人們對再生醫學的認知不斷提高和進步。再生醫學專注於修復和替換受損的細胞、組織和器官，其中 MSCs 因其多功能而發揮關鍵作用。該領域的臨床試驗和研究活動激增，旨在利用 MSCs 的潛力用於各種治療應用。人們對此類再生解決方案的興趣日益濃厚，促進了 MSC 治療市場的擴張。

技術進步也有助於推動 MSC 治療市場向前發展。幹細胞分離、培養和操作技術的創新正在提高 MSC 治療的效率和有效性。依照良好生產規範 (GMP) 開發產品可確保始終如一的品質和安全，從而促進更廣泛的臨床應用。這些技術進步不僅改善了現有的治療方法，而且為新的治療應用鋪平了道路，增加了對 MSC 治療的整體需求。

此外，MSC 治療市場也受益於支持性的法規環境和對幹細胞研究的資金增加。政府和研究機構正在實施政策，鼓勵臨床試驗並加速新幹細胞療法的核准。這種良好的環境促進了創新，使得 MSC 療法能夠高效開發和商業化。此外，公共和私營部門的投資活性化正在刺激研究計劃和合作，確保新的 MSC 療法的穩定供應。

間質幹細胞治療市場：分析概述

  • 根據類型，同種異體預計將在 2024 年佔據整體市場主導地位，佔據 73.83% 的最大收益佔有率，並預計在預測期內以最快的複合年成長率成長。同種異體間質幹細胞(MSC) 在治療中的應用日益廣泛，推動了市場的成長，因為它們可以從健康捐贈者那裡獲取並應用於多名患者。這減少了對個人化細胞採購的需求，使治療更加便捷且更具成本效益。
  • 以原料計算，脂肪部分將在 2024 年佔據整個市場的主導地位，收益佔有率最大，為 37.71%，預計在預測期內將以最快的複合年成長率成長。脂肪幹細胞 (ADSC) 市場因其高產量和多功能不斷擴大，為各種慢性和與老齡化相關的疾病提供了有效的治療方法。細胞處理和製造技術的進步提高了 ADSC 療法的可及性和可用性，進一步推動了市場成長。
  • 2024 年，整形外科和肌肉骨骼疾病領域按適應症佔據第二大市場佔有率（25.56%）。隨著全球肌肉骨骼疾病負擔的增加，整形外科繼續成為 MSC 治療的主要成長領域。
  • 2024 年，亞太地區佔據了最大的市場佔有率，為 71.56%。在政府支持、醫療保健投資增加以及當地臨床活動活性化的推動下，市場正在快速成長。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章 市場促進因素、趨勢與範圍

  • 市場區隔和範圍
  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 產業分析工具
    • SWOT分析；按因素（政治、法律、經濟、技術）
    • 波特五力分析
    • COVID-19影響分析

間質幹細胞治療市場：按類型分類的業務分析

  • 細分儀表板
  • 全球間質幹細胞治療趨勢分析
  • 全球間質幹細胞治療市場規模及趨勢分析（2018-2030）
  • 自體移植
  • 同種異體

間質幹細胞治療市場：原料業務分析

  • 細分儀表板
  • 全球間質幹細胞治療趨勢分析
  • 全球間質幹細胞治療市場規模及趨勢分析（2018-2030）
  • 骨髓
  • 臍帶
  • 胖的
  • 其他成分

間質幹細胞治療市場：依適應症進行的商業分析

  • 細分儀表板
  • 全球間質幹細胞治療趨勢分析
  • 全球間質幹細胞治療市場規模及趨勢分析（2018-2030）
  • 整形外科和肌肉骨骼疾病
  • 心血管疾病
  • 神經系統和中樞神經系統疾病
  • 血液/免疫疾病
  • 其他適應症

第7章間間質幹細胞治療市場：區域評估與趨勢分析（按類型、來源和適應症）

  • 區域儀表板
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
  • 歐洲
    • 英國
    • 德國
  • 亞太地區
    • 日本
    • 韓國
  • 其他國家

第8章 競爭態勢

  • 公司/競爭對手分類
  • 戰略地圖
  • 公司地位分析（2024年）
  • 公司簡介/上市公司
    • MEDIPOST, Inc.
    • PHARMICELL Co., Ltd
    • Antrogen
    • CORESTEMCHEMON Inc.
    • NIPRO Corporation
    • STEMPEUTICS RESEARCH PVT LTD
    • JCR Pharmaceuticals Co Ltd
    • Mesoblast, Inc.
    • Cell Tech Pharmed
    • HOLOSTEM Srl
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-554-9

Mesenchymal Stem Cell Therapy Market Growth & Trends:

The global mesenchymal stem cell therapy market size is anticipated to reach USD 296.6 million by 2030 and is projected to grow at a CAGR of 23.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The mesenchymal stem cell (MSC) therapy market is experiencing significant growth, driven by several key factors. One major driver is the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, autoimmune disorders, and orthopedic ailments. MSCs possess unique regenerative and immunomodulatory properties, making them promising candidates for treating these chronic conditions. Their ability to differentiate into various cell types and promote tissue repair has spurred interest in MSC-based therapeutics. As the global burden of chronic illnesses continues to rise, the demand for innovative treatments like MSC therapy is expected to grow correspondingly.

Another significant factor propelling the MSC therapy market is the growing awareness and advancement in regenerative medicine. Regenerative medicine focuses on repairing or replacing damaged cells, tissues, or organs, and MSCs play a crucial role due to their multipotent nature. The field has witnessed a surge in clinical trials and research activities, aiming to harness the potential of MSCs in various therapeutic applications. This heightened focus on regenerative solutions is contributing to the expansion of the MSC therapy market.

Technological advancements have also been instrumental in driving the MSC therapy market forward. Innovations in stem cell isolation, culture, and manipulation techniques have enhanced the efficiency and effectiveness of MSC therapies. The development of Good Manufacturing Practice (GMP)-compliant products ensures consistent quality and safety, facilitating broader clinical adoption. These technological strides not only improve existing treatments but also open new avenues for therapeutic applications, thereby increasing the overall demand for MSC therapies.

Furthermore, the MSC therapy market benefits from a supportive regulatory environment and increased funding for stem cell research. Governments and institutions are implementing policies that facilitate clinical trials and expedite approvals for new stem cell treatments. This favorable landscape encourages innovation and allows for the efficient development and commercialization of MSC therapies. Additionally, heightened investment from both public and private sectors fosters research initiatives and collaborations, ensuring a steady pipeline of new MSC treatments.

Mesenchymal Stem Cell Therapy Market Report Highlights:

  • Based on type, allogenic segment dominated the overall market with the largest revenue share of 73.83% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of allogenic mesenchymal stem cells (MSCs) in therapy is driving market growth due to their ability to be sourced from healthy donors and applied to multiple patients. This reduces the need for personalized cell sourcing, making treatments more accessible and cost-effective.
  • Based on source, the adipose segment dominated the overall market with the largest revenue share of 37.71% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The market for adipose-derived stem cells (ADSCs) is expanding due to their high yield and multipotency, offering effective treatments for various chronic diseases and age-related conditions. Ongoing advancements in cell processing and manufacturing techniques are enhancing the accessibility and affordability of ADSC therapies, further driving market growth.
  • In 2024, orthopedic and musculoskeletal disorders segment held the second-largest market share of 25.56% in the disease indication segment. As the burden of musculoskeletal diseases rises globally, the orthopedic segment continues to be a major growth area within the MSC therapy landscape.
  • Asia Pacific accounted for the largest market share of 71.56% in 2024. The market is experiencing rapid growth fueled by government support, rising healthcare investments, and increasing local clinical activity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Source
    • 1.2.3. Disease Indication
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Broad Therapeutic Potential Across Multiple Diseases
      • 3.3.1.2. Advancements in Cell Culture & Manufacturing Technologies
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Stringent Regulatory Frameworks
  • 3.4. Industry Analysis Tools
    • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 4.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Autologous
    • 4.4.1. Global Autologous Market, 2018 - 2030 (USD Million)
  • 4.5. Allogenic
    • 4.5.1. Global Allogenic Market, 2018 - 2030 (USD Million)

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 5.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
  • 5.4. Bone Marrow
    • 5.4.1. Global Bone Marrow Market, 2018 - 2030 (USD Million)
  • 5.5. Umbilical Cord
    • 5.5.1. Global Umbilical Cord Market, 2018 - 2030 (USD Million)
  • 5.6. Adipose
    • 5.6.1. Global Adipose Market, 2018 - 2030 (USD Million)
  • 5.7. Others Sources
    • 5.7.1. Global Others Sources Market, 2018 - 2030 (USD Million)

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 6.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
  • 6.4. Orthopedic and Musculoskeletal Disorders
    • 6.4.1. Global Orthopedic and Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Global Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 6.6. Neurological and CNS Disorders
    • 6.6.1. Global Neurological and CNS Disorders Market, 2018 - 2030 (USD Million)
  • 6.7. Hematological / Immune Disorders
    • 6.7.1. Global Hematological / Immune Disorders Market, 2018 - 2030 (USD Million)
  • 6.8. Others Indications
    • 6.8.1. Global Others Indications Market, 2018 - 2030 (USD Million)

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. South Korea
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. South Korea Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Rest of World
    • 7.6.1. Rest of World Mesenchymal Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. MEDIPOST, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. PHARMICELL Co., Ltd
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Antrogen
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. CORESTEMCHEMON Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. NIPRO Corporation
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. STEMPEUTICS RESEARCH PVT LTD
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. JCR Pharmaceuticals Co Ltd
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Mesoblast, Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Cell Tech Pharmed
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. HOLOSTEM S.r.l.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. Takeda Pharmaceutical Company Limited
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 5 Global mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 6 Global mesenchymal stem cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 10 North America mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S. mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 13 U.S. mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 14 Europe mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 16 Europe mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 17 Europe mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 18 UK mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 19 UK mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 20 UK mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 21 Germany mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 22 Germany mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 23 Germany mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 26 Asia Pacific mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 28 Japan mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Japan mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 30 Japan mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 31 South Korea mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 32 South Korea mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 33 South Korea mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 34 Rest of World mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 35 Rest of World mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 36 Rest of World mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 37 Rest of World mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 38 Participant's overview
  • Table 39 Financial performance
  • Table 40 Key companies undergoing expansions
  • Table 41 Key companies undergoing acquisitions
  • Table 42 Key companies undergoing collaborations
  • Table 43 Key companies launching new products
  • Table 44 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Mesenchymal stem cell therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Genomics - Industry value chain analysis
  • Fig. 15 Mesenchymal stem cell therapy market driver analysis
  • Fig. 16 Mesenchymal stem cell therapy market restraint analysis
  • Fig. 17 Mesenchymal stem cell therapy market: Porter's analysis
  • Fig. 18 Mesenchymal stem cell therapy market: Type outlook and key takeaways
  • Fig. 19 Mesenchymal stem cell therapy market: Type market share analysis, 2023 - 2030
  • Fig. 20 Global mesenchymal stem cell therapy by autologous market, 2018 - 2030 (USD Million)
  • Fig. 21 Global mesenchymal stem cell therapy by allogenic market, 2018 - 2030 (USD Million)
  • Fig. 22 Mesenchymal stem cell therapy market: Source outlook and key takeaways
  • Fig. 23 Mesenchymal stem cell therapy market: Source market share analysis, 2023 - 2030
  • Fig. 24 Global mesenchymal stem cell therapy by umbilical cord market, 2018 - 2030 (USD Million)
  • Fig. 25 Global mesenchymal stem cell therapy by adipose market, 2018 - 2030 (USD Million)
  • Fig. 26 Global mesenchymal stem cell therapy by other sources market, 2018 - 2030 (USD Million)
  • Fig. 27 Mesenchymal stem cell therapy market: Disease indication outlook and key takeaways
  • Fig. 28 Mesenchymal stem cell therapy market: Disease indication market share analysis, 2023 - 2030
  • Fig. 29 Global mesenchymal stem cell therapy by orthopedic and musculoskeletal disorders market, 2018 - 2030 (USD Million)
  • Fig. 30 Global mesenchymal stem cell therapy by cardiovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 31 Global mesenchymal stem cell therapy by neurological and CNS disorders market, 2018 - 2030 (USD Million)
  • Fig. 32 Global mesenchymal stem cell therapy by hematological / immune disorders market, 2018 - 2030 (USD Million)
  • Fig. 33 Global mesenchymal stem cell therapy by other indications market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. key country dynamics
  • Fig. 37 U.S. mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Europe mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 UK key country dynamics
  • Fig. 40 UK mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany key country dynamics
  • Fig. 42 Germany mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Asia-Pacific mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Japan key country dynamics
  • Fig. 45 Japan mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea key country dynamics
  • Fig. 47 South Korea mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Rest of World mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Key company categorization
  • Fig. 50 Company market positioning
  • Fig. 51 Market participant categorization
  • Fig. 52 Strategy framework